Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04952311
Other study ID # M2020521
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 1, 2019
Est. completion date September 30, 2021

Study information

Verified date June 2021
Source Peking University Third Hospital
Contact Yu Fu
Phone +86 15611908699
Email lilac_fu@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to test whether ticagrelor combined with aspirin can reduce the recurrence rate of stroke within 3 months compared with clopidogrel combined with aspirin in patients at high risk of non-disablement ischemic cerebrovascular events who carry the CYP2C19 function loss allele within 24 hours of onset.


Description:

This study was a multicenter, double-blind, double-simulated, randomized controlled study. To test whether ticagrelor combined with aspirin reduces the recurrence rate of stroke within 3 months compared with clopidogrel combined with aspirin in patients with a high risk of noncrippling ischemic cerebrovascular events with CYP2C19 loss within 24 hours of onset.


Recruitment information / eligibility

Status Recruiting
Enrollment 10878
Est. completion date September 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: 1. Age =40; 2. Patients with acute non-disabling ischemic stroke or transient ischemic attack (TIA) who meet the following definitions: - Acute non-disabling ischemic stroke: NIHSS score =3 at enrolment, - Mediate-high risk of stroke TIA: ABCD2 score =4; 3. Study drugs can be administered within 24 hours of symptoms * appearing; 4. CYP2C19 loss allele carriers; 5. Signed informed consent. Exclusion Criteria: 1. Hemorrhage or other pathological brain disease, such as vascular malformation, tumor, abscess, or other common non-ischemic brain disease (e.g., multiple sclerosis), as diagnosed by CT or MRI of the head at baseline. 2. There were only isolated sensory symptoms (e.g., numbness), isolated visual changes, isolated dizziness or vertigo, but no evidence of acute infarction on baseline head CT or MRI. 3. Mild stroke /TIA due to angioplasty/vascular surgery. 4. Pre-onset MRS score > Two points. Pre-onset MRS score [Note: According to the patient's pre-onset history assessment, if patients with MRS> score of 2 were not included] 5. There are contraindications for the use of clopidogrel, ticagrelor or aspirin. - a known history of allergies; - Severe liver or renal insufficiency; - (Severe liver dysfunction is defined as ALT value > 2 times the upper normal limit or AST value > 2 times the upper normal limit; Severe renal insufficiency was defined as creatinine > 1.5 times the upper normal limit); - Severe heart failure (NYHA rating ? and AA); - A history of coagulation disorders or systemic bleeding; - A history of thrombocytopenia or neutropenia; - A history of blood-system disease or abnormal liver function caused by drugs; - Leukopenia (lt; 2×109/L) or thrombocytopenia (< 100 x 109 / L); Hematocrit < 30%. 7. There are clear indications of anticoagulant therapy (suspected cardiac embolism, such as atrial fibrillation, known artificial heart valves, suspected endocarditis, etc.). 8. Have a history of intracranial hemorrhage or a history of amyloid cerebrovascular disease. 9. A history of aneurysms (including intracranial and peripheral aneurysms). A history of asthma or COPD (chronic obstructive pulmonary disease). 11. High risk bradyarrhythmias, such as disordered sinus syndrome, second or third degree atrioventricular block, bradycardia associated syncope due to absence of a pacemaker. 12. A history of hyperuric acid nephropathy (fasting serum uric acid content in men and menopausal women on two different days under the condition of anopurine diet > 420umol/L(7.0mg/ dL), premenopausal women > 357 umol/L (6.0 mg/dl).) . 13. It is expected that it will be possible for a long time (gt; 7 days) take any non-steroidal anti-inflammatory drugs other than aspirin. 14. Surgical or endovascular treatment is expected to be required in the next 3 months. 15. Discontinuation of the experimental drug may be required for other planned surgical or interventional therapies. 16. Severe non-cardio-cerebrovascular diseases with an expected survival time of less than 3 months. 17. Inability to understand and/or comply with study procedures and/or follow-up due to mental illness, cognitive or emotional disorder. 18. Two or more antiplatelet drugs were taken within 72 hours before enrolment. 19. Heparin or oral anticoagulants were used within 10 days before enrollment. 20. Patients who had received intravenous or arterial thrombolysis or mechanical thrombectomy within 24 hours before enrollment. 21. A history of gastrointestinal bleeding within 3 months before enrollment or major surgery within 30 days. 22. Confirmed or suspected acute coronary syndrome. 23. Participated in other clinical drug studies in the past 30 days. 24. Experimental drug or instrument tests are under way. 25. Women of childbearing age, pregnancy or breastfeeding who have negative pregnancy tests but refuse to use effective contraceptives.

Study Design


Intervention

Drug:
Tagrelor combined with aspirin
Combination of ticagrelor (first 180mg a day, 90mg/ d, 2 times/d) with aspirin (first 75 to 300mg/ d, 75mg/ d, 2 days/d) for 21 days followed by ticagrelor (90mg/ d, 2 times/d) alone for 3 months
Clopidogrel combined with aspirin
Clopidogrel (first dose 300mg daily, 75mg/ d from day 2) was combined with aspirin (first dose 75-300mg/ d, 75mg/ d from day 2) for 21 days, followed by clopidogrel (75mg/ d) alone for up to 3 months

Locations

Country Name City State
China Peking University Third Hospital Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking University Third Hospital Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary new stroke event Any new stroke event (ischemic stroke or hemorrhagic stroke) within 3 months 3 months
Secondary new stroke event Any new stroke event (ischemic stroke or hemorrhagic stroke) within 1 year 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT00859885 - International PFO Consortium N/A
Not yet recruiting NCT03605355 - Feasibility Study on the Medical and Economic Consequences of Outpatient Management of TIAs and Minor Strokes
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Completed NCT04078737 - Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II Phase 3
Completed NCT02141932 - Pocket-size Cardiovascular Ultrasound in Stroke N/A
Recruiting NCT01954329 - Markers in the Diagnosis of TIA N/A
Completed NCT02011256 - Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack N/A
Completed NCT01918891 - Center for Stroke Disparities Solution - Community Transitions Intervention N/A
Recruiting NCT01526824 - Lovaza's Effect on Clopidogrel in a Neuro Population Phase 0
Completed NCT01020851 - The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial N/A
Completed NCT00597974 - Neurological Outcome With Carotid Artery Stenting N/A
Completed NCT00211731 - Preventing Recurrent Stroke in Minority Populations N/A
Active, not recruiting NCT03635749 - Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis Phase 3
Completed NCT03153020 - Determinants of Adherence to Post-stroke/Transient Ischemic Attack Secondary Prevention Treatment: Cohort Study in the Rhône
Recruiting NCT04075500 - Optimal Detection of Atrial Fibrillation in TIA N/A
Recruiting NCT06091319 - Florbetaben for Imaging of Vascular Amyloid
Completed NCT04604015 - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt N/A
Completed NCT00885456 - Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT Phase 2
Completed NCT05620966 - EEG to Diagnose TIA and Stroke